Physician

Devi K Jhaveri, D.O.

According to 2025 Medicare claims, Devi Jhaveri, D.O. (NPI: 1073749834) practices allergy/immunology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Lake, OH. This provider's primary affiliated billing organization is ALLERGY IMMUNOLOGY ASSOCIATES INC (NPI: 1922212760; TIN: 34-1151148) and primary practice location at 44124-4034.

Jhaveri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 147 traditional Medicare patients, billed 15,697 HCPCS/CPT codes, and received $659,286 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,461 prescription claims across 183 beneficiaries totaling $518,922 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 92 claims. Open Payments data shows 137 records totaling $7,762. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,915 to $659,286. Similarly, Part D prescription costs have risen steadily, from $2,822 to $518,922. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $177 and ending at $1,769.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	36	367	$5,915
2016	168	5,620	$134,417
2017	240	15,125	$345,722
2018	198	10,592	$259,925
2019	262	14,616	$371,837
2020	186	10,914	$235,515
2021	193	14,232	$370,484
2022	170	11,700	$360,362
2023	156	14,967	$448,038
2024	147	15,697	$659,286

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	30	$2,822
2016	82	273	$31,812
2017	117	588	$214,320
2018	122	591	$86,840
2019	183	825	$121,755
2020	170	1,404	$312,277
2021	172	1,299	$425,601
2022	170	1,257	$576,627
2023	192	1,400	$616,057
2024	183	1,461	$518,922

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	63	$52,742
2023	N/R	33	$56,695
2024	N/R	92	$546,381

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	234	$87
94010	Test to measure expiratory airflow and volume	33	35	$18
95012	Test to measure the level of nitric oxide gas	33	35	$13
95165	Professional service for preparation and provision of 1 or more antigens	19	301	$9
96160	Administration and interpretation of patient-focused health risk assessment	47	81	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	26	812	$102,968
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	98	4,080	$85,668
Dupixent Pen	Dupilumab	15	420	$55,263
Spiriva Respimat	Tiotropium Bromide	57	2,400	$37,930
Breo Ellipta	Fluticasone/Vilanterol	53	2,130	$27,682

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1554	Injection, immune globulin (asceniv), 500 mg	N	N/R	24	$416,082
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	12	$83,696
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	11	$45,016
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	23	$1,074
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	11	$400

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	136	$7,622	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$140	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Devi K. Jhaveri, D.O.?

Tedicare shows public-source Medicare data for Devi K. Jhaveri, D.O. (NPI 1073749834), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Devi K. Jhaveri, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Devi K. Jhaveri, D.O.?

Devi K. Jhaveri, D.O. is linked to ALLERGY IMMUNOLOGY ASSOCIATES INC (billing NPI 1922212760) in the available physician profile data.

Does Devi K. Jhaveri, D.O. have Open Payments data?

Devi K. Jhaveri, D.O. has 137 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.